Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Pharming Group Q3 revenue rises on US demand; tightens guidance

By Reuters News


Overview

  • Netherlands biotech firm's preliminary Q3 revenue rose 21% yr/yr

  • RUCONEST revenue up 14% and Joenja revenue up 58%, driven by demand and new launches

  • Operating profit nearly doubled, rising 89% yr/yr


Outlook

  • Pharming tightens 2026 revenue guidance to $380 mln-$390 mln from $375 mln-$395 mln

  • Company expects 2026 operating expenses of $310 mln-$315 mln, including $35 mln extra R&D investment

  • Company expects RUCONEST revenue stabilization and return to growth in H2 2026


Result Drivers

  • RUCONEST DEMAND STABILIZATION - Co said RUCONEST revenue growth was driven by stabilized U.S. demand, strong retention in high-burden patient segment, and new patient/prescriber additions

  • JOENJA LAUNCHES AND DEMAND - Co attributed Joenja revenue growth to launches in Germany and Japan, increased U.S. uptake, and expanded pediatric dosing

  • GROSS PROFIT IMPACT - Gross profit rose mainly due to higher revenues, partially offset by manufacturing-related inventory impairments


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

9M Net Income

$18.90 mln

9M Gross Profit

$243.70 mln

9M Operating Profit

$26.30 mln


Analyst Coverage

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy."

  • Wall Street's median 12-month price target for Pharming Group N.V. is €2.00, about 89.8% above its October 26 closing price of €1.05

  • The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 21 three months ago


Reuters Recommended Reads

  • Oct 26 - GSK, Hansoh's bone cancer drug delays disease progression in late-stage China study

  • Oct 25 - Roche says divarasib cut risk of death 44% in lung cancer trial


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.